LXRX (Lexicon Pharmaceuticals, Inc.) Stock Financials & Earnings

LXRXLexicon Pharmaceuticals, Inc.

Mkt Cap$704M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$71M

Net Income (TTM)-$69M

EPS (TTM)-$0.19

Free Cash Flow (TTM)-$44M

Gross Margin63.1%

Op. Margin-94.4%

Net Margin-96.8%

FCF Margin-62.1%

P/S Ratio (TTM)9.9x

P/E Ratio (TTM)—

YoY Rev Growth+1255.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$28K	-$75K	-$30M
Q1 23	$24K	$24K	-$31M
Q2 23	$317K	$309K	-$44M
Q3 23	$162K	$155K	-$50M
Q4 23	$702K	-$14M	-$47M
Q1 24	$1M	$955K	-$45M
Q2 24	$2M	$1M	-$55M
Q3 24	$2M	$2M	-$64M
Q4 24	$27M	$621K	-$33M
Q1 25	$1M	$1M	-$26M
Q2 25	$29M	$29M	$4M
Q3 25	$14M	$14M	-$12M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$14M	—	—	$16M
Q1 23	$12M	$19M	—	—
Q2 23	$15M	$30M	—	—
Q3 23	$18M	$3M	$30M	—
Q4 23	$15M	—	—	—
Q1 24	$14M	$32M	—	—
Q2 24	$18M	—	—	$39M
Q3 24	$26M	—	—	$40M
Q4 24	$27M	—	—	—
Q1 25	$15M	—	—	$12M
Q2 25	$16M	—	—	$9M
Q3 25	$19M	—	—	$8M

Revenue Segments

Quarter	License	Product
Q2 25	$28M	$1M
Q3 25	$13M	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$26M	$80M	$106M
Q2 23	$102M	$154M	$257M
Q3 23	$21M	$197M	$218M
Q4 23	$22M	$148M	$170M
Q1 24	$96M	$259M	$356M
Q2 24	$36M	$274M	$310M
Q3 24	$35M	$224M	$258M
Q4 24	$67M	$171M	$238M
Q1 25	$63M	$132M	$195M
Q2 25	$21M	$118M	$139M
Q3 25	$50M	$66M	$116M
Q4 25	$34M	$62M	$96M

Shares Outstanding

Revenue Per Employee

Revenue / Employee